Pharmaceutical 2011 - China Pharmaceutical R&D Summit

Clinical & Regulatory Summit
Understand the Regulatory Environment in China
Hear from a tuned-in Clinical CRO on the changing regulatory environment; a US company's insight on conducting global trials in Asia, and a leading consultant's strategy to bring Chinese drugs and biologics to US market.
Benefit from these Tried & Proven Clinical Strategies and Case Studies:
FIH Study in China: from IND Application to Study Completion
Getting Ready for Global Trials in China
Conducting Health Economics & Outcomes Research in China
Developing Risk Management Plan in Clinical Trials
Bridging China Data with Global Data - Global Simultaneous Development
Trials & Tribulations of Starting Clinical Trials in a New Geographic Region
Discovery to Preclinical Development & Partnerships
Hear the Latest in NCE Development from these Domestic Chinese Companies:
Hec Pharma, Ascentage Pharma, IMPACT Therapeutics, Sunwei Therapeutics, Argusina Shanghai, Nanjing Changao Pharmaceutical, Luye Pharma Group and TOT Shanghai
Get Exciting Partnering Strategies and Updates from:
Roche, Simcere Pharmaceuticals, Pfizer, AstraZeneca, Fosun Pharmaceutical, Synta Pharmaceuticals, DCB Taiwan, GSK and Eli Lilly
Biologics & Biosimilars Development
Hear Rarely-Told Stories of China's Biologics Development:
History of Licartin - a I-131 Labeled Anti-CD147 Launched in China for Liver Cancer
EGFR mAb - a 10-Year Development Effort
A 10-year Development History of Etanercept in China
TPO - an Innovative Biopharmaceutical Product in China
Interleukin-7 Receptor: A New Therapeutic Target Using Biological Approach
Developing Oral Insulin in China - Experiences and Lessons
Learn from Success Stories of Large Molecule Development from Around the World:
Alternatives to Antibodies - High Affinity Mirror-Image Oligonucleotides
Story of Abgenix: from XenoMouse to Panitumumab and Beyond
Development of Cell Therapy in China
Peptide Therapeutics in China
A never-before line-up of over 75 Speakers from international pharma, MNCs in China, and domestic Chinese pharma/biotechs will be sharing their expert opinions and experiences on clinical challenges, regulatory updates , NCE discovery efforts, preclinical partnerships, biosimilars development and more!

With shared Keynote and Plenary Sessions over 3 days, participants will be able to choose the conference of their choice or mix-and-match sessions from all 3 conferences, while taking advantage of the shared sessions and networking breaks to meet with other executives and scientists at the event.

With proven attendance from top-level executives from China's major pharma and biotech companies, this is THE MEETING PLACE to network and share experiences, meet potential partners and foster business relationships.